| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Būtiski notikumi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2008-10-30 08:35:51 |
| Versijas komentārs | |
| Teksts |
JSC „Grindeks” forecasts that the year 2008 will end successfully and the turnover in the amount of LVL 64 million will be reached. Such a result will be obtained due to successful business activity in Russia, the rest CIS states and product sales in other world markets. In order to achieve the current turnover dynamics also in the future, Chairman of the Council of JSC „Grindeks” Kirovs Lipmans emphasizes: “The market strategy of „Grindeks” has justified itself, therefore we will concentrate our activity on both, the existing markets and the new, prospective market acquisition such as China and Turkey, as well as entering smaller South Asian markets, for example, Vietnam also in the future”. Upon registering Mildronate® and implementation of business activity in China, Kirovs Lipmans, who has just returned from a business visit in Beijing sees further development opportunities of the company: “If everything will take place as it is currently planned, a manufacturing joint company could be established in the future, as well as registration of the second brand product of “Grindeks” Ftorafur® started in China.” In order to maintain the previous development rates of the company within a long term, “Grindeks” will annually invest 9-11% of the turnover in research and development also in the future. Chairman of the Council remarks: “Competition in the pharmacy sector is intense, therefore our strategy must be aggressive and the plans – ambitious. Purposeful investments must be made in research and technologies so that “Grindeks” duplicated and even triplicated the turnover within the next five years – it must be thought about both, development of new products and continuous improvement of infrastructure. That is our perspective.” About “Grindeks” JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of “Grindeks’s” products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. “Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. “Grindeks” shares are listed in the Official List of Riga Stock Exchange. You are kindly invited to www.grindeks.lv to find out more about our company! Contacts: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phones: +371 67083370, + 371 29256012 e-mail: laila.klavina@grindeks.lv |
| Pielikumi |
|